Integra Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>IL</div>
IART -- USA Stock  

USD 68.34  0.90  1.30%

Integra LifeSciences is scheduled to announce its earnings today. The next earnings report is expected on the 6th of May 2021. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to review Integra LifeSciences under the newest economic conditions. Should we be more optimistic in anticipation of a recovery?
Published over a week ago
View all stories for Integra Lifesciences | View All Stories
Would you shadow Integra LifeSciences analysts?
On a scale of 0 to 100, Integra LifeSciences holds a performance score of 19. The company retains a Market Volatility (i.e. Beta) of 1.1918, which attests to a somewhat significant risk relative to the market. Let's try to break down what Integra's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Integra LifeSciences will likely underperform. Although it is vital to follow Integra LifeSciences current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Integra LifeSciences technical indicators, you can presently evaluate if the expected return of 0.47% will be sustainable into the future. Please utilizes Integra LifeSciences information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to make a quick decision on whether Integra LifeSciences Holdings current trending patterns will revert.
What is the right price you would pay to acquire a share of Integra Lifesciences? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Integra Lifesciences this year

Annual and quarterly reports issued by Integra Lifesciences are formal financial statements that are published yearly and quarterly and sent to Integra stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Integra Lifesciences often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Integra utilizes its cash?

To perform a cash flow analysis of Integra Lifesciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Integra Lifesciences is receiving and how much cash it distributes out in a given period. The Integra Lifesciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Integra Lifesciences Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. Integra Lifesciences reported Net Cash Flow from Operations of 266.15 Million in 2020

What is driving Integra Lifesciences Investor Appetite?

Earning per share calculations of the firm is based on official Zacks consensus of 6 analysts regarding Integra LifeSciences' future annual earnings. Given the historical accuracy of 97.79%, the future earnings per share of the company is estimated to be 2.3583 with the lowest and highest values of 2.32 and 2.48, respectively. Please note that this consensus of annual earnings estimates for Integra LifeSciences is an estimate of EPS before non-recurring items and including employee stock options expenses.

Is Integra a risky opportunity?

Let's check the volatility. Integra is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Integra (NASDAQ:IART) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of an Integra LifeSciences stock makes you a part-owner of that company.

Integra LifeSciences Holdings Current Consensus

Here is the newest trade recommendation based on an ongoing consensus estimate among financial analysis covering Integra LifeSciences. The Integra consensus assessment is calculated by taking the average estimates from all of the analysts covering Integra LifeSciences

Strong Buy
Strong Sell
Strong Buy440.0
Strong Sell110.0

How will Integra private investors react to the next drop?

Newest potential upside is at 3.35. Integra LifeSciences Holdings has relatively low volatility with skewness of -0.05 and kurtosis of -0.07. However, we advise all investors to independently investigate Integra LifeSciences Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Takeaway

Whereas some other companies in the medical devices industry are either recovering or due for a correction, Integra LifeSciences may not be performing as strong as the other in terms of long-term growth potentials. While some private investors may not share our view we believe it may be a good time to short Integra as the risk-reward trade off is not appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Integra LifeSciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Integra Lifesciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to